Daniel Eitutis

Associate
Full contact info

Experience

ONE Finance Acquired by Hazel to Create All-in-One Fintech Platform

April 6, 2022

Cooley advised financial-services mobile app ONE Finance on its completed acquisition by Hazel, an independent fintech launched in partnership with Walmart and investment firm Ribbit Capital. Peter Werner and Luke Blackett led the Cooley team advising ONE.

Read more

Related contacts

Peter H. Werner
Partner in Charge – San Francisco, San Francisco
Luke X. Blackett
Associate, San Francisco
Jamie Leigh
Partner, San Francisco
Blake Martell
Partner, San Francisco
Megan Browdie
Partner, Washington, DC
Obrea Poindexter
Partner, Washington, DC
David Wilson
Partner, London
Ross Eberly
Partner, Los Angeles Santa Monica
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Tom Epps
Partner, London
Sean Ruff
Partner, Washington, DC
Kevin King
Partner, Washington, DC
David Navetta
Partner, Colorado
Peter Burns
Of Counsel, Palo Alto
Yulia Makarova
Special Counsel, London
Rebecca Ross
Special Counsel, Washington, DC
Adam Fleisher
Partner, Washington, DC
Daniel Eitutis
Associate, San Francisco
Ajay Athavale
Associate, San Francisco
David Dalton
Associate, Los Angeles Santa Monica
Caitlin Courtney
Partner, Palo Alto
Megan Drill
Associate, San Diego
Ehijele Olumese
Associate, Los Angeles Downtown
Chelsea André
Associate, Colorado
Grace Hunter
Associate, Washington, DC
Neelam Atwal
Associate, London
Liz Paisner
Associate, New York
Alex Mitrea
Associate, London
Joshua Elefant
Associate, Palo Alto
Casey Warsh
Associate, Colorado

Related Practices & Industries

Vera Therapeutics – $48 Million IPO

May 13, 2021

Cooley advised Vera Therapeutics on its $47.85 million initial public offering of 4,350,000 shares of class A common stock. Vera Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol VERA, is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Partners Jodie Bourdet and Carlton Fleming led the Cooley team.

Related contacts

Jodie Bourdet
Partner, San Francisco
Rachel M. Burns
Special Counsel, San Francisco
Daniel Eitutis
Associate, San Francisco
Sam Miller
Associate, San Francisco

Related Practices & Industries

Spruce Biosciences – $130 Million IPO

Cooley advised Spruce Biosciences on its $103.5 million initial public offering of 6,900,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Spruce, whose securities now trade on the Nasdaq Global Select Market under the symbol “SPBR,” is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Partners Jason Kent and Kristin VanderPas led the Cooley team.

Related contacts

Jason Kent
Partner, New York
Kristin VanderPas
Partner, San Francisco
Daniel Eitutis
Associate, San Francisco

Related Practices & Industries